MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52 Week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non Steroidal Anti-inflammatory Drugs (NSAIDs)
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms MAXIMISE
- Sponsors Novartis
- 14 Nov 2017 Planned primary completion date changed from 20 May 2019 to 17 Aug 2018.
- 19 Jul 2017 This trial has been Discontinued in Denmark, according to European Clinical Trials Database
- 08 Feb 2017 Status changed from not yet recruiting to recruiting.